254 related articles for article (PubMed ID: 36575406)
21. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
[TBL] [Abstract][Full Text] [Related]
22. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
[TBL] [Abstract][Full Text] [Related]
23. Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies.
Hammarström H; Krifors A; Athlin S; Friman V; Golestani K; Hällgren A; Otto G; Oweling S; Pauksens K; Kinch A; Blennow O
Clin Infect Dis; 2023 Feb; 76(3):e1252-e1260. PubMed ID: 35594562
[TBL] [Abstract][Full Text] [Related]
24. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia.
Jin F; Liu XH; Chen WC; Fan ZL; Wang HL
Int J Infect Dis; 2019 Nov; 88():141-148. PubMed ID: 31442630
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
26. VV-ECMO combined with prone position ventilation in the treatment of Pneumocystis jirovecii pneumonia: A case report.
Jia L; Zhang Z; Bai Y; Du Q
Medicine (Baltimore); 2022 Jan; 101(1):e28482. PubMed ID: 35029898
[TBL] [Abstract][Full Text] [Related]
27. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
28. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
29. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
[TBL] [Abstract][Full Text] [Related]
30. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
31. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
32. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis.
Chen X; Shu X; He L; Yang H; Lu X; Wang G; Ge Y
Rheumatology (Oxford); 2023 Oct; 62(10):3302-3309. PubMed ID: 36734589
[TBL] [Abstract][Full Text] [Related]
33. Low-dose trimethoprim-sulfamethoxazole for the treatment of
Sohani ZN; Butler-Laporte G; Aw A; Belga S; Benedetti A; Carignan A; Cheng MP; Coburn B; Costiniuk CT; Ezer N; Gregson D; Johnson A; Khwaja K; Lawandi A; Leung V; Lother S; MacFadden D; McGuinty M; Parkes L; Qureshi S; Roy V; Rush B; Schwartz I; So M; Somayaji R; Tan D; Trinh E; Lee TC; McDonald EG
BMJ Open; 2022 Jul; 12(7):e053039. PubMed ID: 35863836
[TBL] [Abstract][Full Text] [Related]
34. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.
Chen YH; Fang XY; Li YT; Liu YL; Hang YP; Xiao YP; Cao XW; Zhong QS; Hu LH
Braz J Microbiol; 2020 Sep; 51(3):1061-1069. PubMed ID: 32363569
[TBL] [Abstract][Full Text] [Related]
36. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
Arnold LM; Hoshina Y; Lee H; Colman H; Mendez J
J Neurooncol; 2024 Mar; 167(1):211-217. PubMed ID: 38363493
[TBL] [Abstract][Full Text] [Related]
37. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
[TBL] [Abstract][Full Text] [Related]
38. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
Liu A; Sun R; Cao G; Liu X; Zhu H; Yang J
BMC Infect Dis; 2022 Jun; 22(1):546. PubMed ID: 35701759
[TBL] [Abstract][Full Text] [Related]
40. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
